$ 27.96
Key Takeaways
Risk factor
High price volatility
Profitability factor
Greatly overvalued vs peers
About
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA, reaso
Target Price
The average target price of STAA is 24 and suggests 13% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre
